沙利度胺对特发性肺间质纤维化的干预作用  

作　　者：史捷[1] 强宁侠[1] 喻敏[1] 

机构地区：[1]陕西中医学院第一附属医院呼吸科,712000

出　　处：《浙江临床医学》2012年第8期906-908,共3页Zhejiang Clinical Medical Journal

摘　　要：目的 探讨沙利度胺对特发性肺纤维化（IPF）的干预作用.方法 IPF患者57例,随机分为沙利度胺联合强的松治疗组（治疗组）37例和单用强的松治疗组（对照组）20例.强的松0.5mg/（kg·d）,口服,4周后减量至0.25mg/kg·d,8周后减量至0.25mg/kg,隔日1次,用至3个月;沙利度胺100mg/d,晚睡前1次服用,12周后减量至50mg/d,用至3个月.3个月后进行疗效评定.结果 沙利度胺联合强的松治疗组临床总有效率、胸部CT显示病变吸收率、肺功能相关指标、血气分析指标与单用强的松的对照组比较差异均有统计学意义（P〈0.05）.结论 沙利度胺联合强的松对IPF的疗效明显优于单用强的松,表明沙利度胺对IPF有干预作用,能控制特发性肺间质纤维化的发展.Objective To investigate the therapeutic effect of Thalidomide plus prednisone on idiopathic pulmonary fibrosis （ IPF ） . Method 57 IPF patients were randomly divided into control group （ n=20, prednisone for oral use, 0.Stag/ kg.d; after 4 weeks, the dosage was changed to 0.25mg/kg.d; and 0.25mg/kg-qod, after 8 weeks, the treatment course was three months ） and treatment group （ n=37, prednisone for oral use according to above-mentioned plan, to add thalidomide for oral use, 100mg/d, the time before retiring; after 12 weeks, the dosage was changed to 50mg/d, the treatment course was three months ） , afer 3 months, to assessment curative effect. Result There were significant differences in clinical total effective rate, absorptivity of focus of infection on thoracic region CT, pulmonary function, and blood gas analysis between the groups （ P〈0.05 ） . Conclusion Thalidomide plus prednisone can prevent pulmonary in terstitial fibrosis.

关 键 词：特发性肺间质纤维化 沙利度胺 强的松 

分 类 号：R563[医药卫生—呼吸系统]